MedTrace Logo

A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3)

NCT01126580 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 807

Last updated 2015-01-16

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if LY2189265 is safe and effective in reducing glycosylated hemoglobin (HbA1c) as compared to metformin in participants with Type 2 Diabetes.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Metformin

DRUG

LY2189265

DRUG

Placebo (oral)

DRUG

Placebo (subcutaneous)

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2011-11-30
Completion
2012-06-30

Countries

  • United States
  • Argentina
  • Brazil
  • Canada
  • Croatia
  • Czechia
  • Finland
  • France
  • Germany
  • India
  • Mexico
  • Poland
  • Puerto Rico
  • Romania
  • Slovakia
  • South Africa
  • South Korea
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01126580 on ClinicalTrials.gov